Company Secretary
London, 4 April 2012 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) ("Hikma"), the FTSE 250 pharmaceuticals company, announces the appointment of Mr. Peter Speirs as Company Secretary of Hikma with effect from 3 April 2012. Mr. Henry Knowles continues in his role as the Group General Counsel of the Company.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs, Company Secretary +44 (0)20 7399 2760
Susan Ringdal, Director of Investor Relations +44 (0)20 7399 2760
About Hikma
Hikma is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non‐branded generic and in‐licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2011, Hikma achieved revenue of $918.0 million and profit attributable to shareholders of $80.1 million.